FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on NRx Pharmaceuticals, Inc. (NRXP)
-
-
-
-
-
-
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
New to The Street's Prestigious Client NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of
-
-
-
-
-
-
-
NRx Pharmaceuticals, Inc. (NRXP) PT Raised to $34 at D. Boral Capital
-
-
-
-
-
-
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
-
-
-
-
-
-
-
NRx Pharmaceuticals (NRXP) and HOPE Announce Agreement to Acquire Interest in Cohen and Associates
-
-
-
-
-
-
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

